EN
Enovis Corporation
ENOV · NYSE
$17.71 +1.61% (+$0.28)
1M -2.91%
Market Cap $1.02B
P/E Ratio -
Div. Yield -
ROE 68.17%
Bulios Fair Price
$26.57
50.0% upside
Current Price
$17.71
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ENOV is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Moderate
5/9Valuation
91 /100
Cheap P/S 0.44x
P/FCF 16.01x
P/B 0.69x
Growth
61 /100
Stable Rev. growth 12.88%
Book val. growth 24.40%
EPS growth N/A
Profitability
32 /100
Weak Gross margin 57.43%
FCF margin 2.77%
Net margin 47.97%
Quality
13 /100
Poor ROIC 3.04%
Asset turnover 0.61x
ROE 68.17%
Debt
48 /100
Moderate Debt/Equity 0.93x
Int. coverage -18.23x
Current ratio 1.98x
Stability
39 /100
Moderate Beta 1.43x
Profitable years 0
Rev. volatility 9.05%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ENOV
Online
Sector
Healthcare
Industry
Medical - Devices
CEO
Damien McDonald
Employees
7,802
Headquarters
Wilmington
Upcoming events
05 NOV
Earnings
Upcoming earnings report